1. Volume 383, Issue 9925, Pages 1297-1304 (April 2014)
Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial 
Katherine Anagnostou, PhD, Sabita Islam, PhD, Yvonne King, RSN, Loraine Foley, PhD, Laura Pasea, BSc, Simon Bond, PhD, Chris Palmer, PhD, John Deighton, BSc, Pamela Ewan, MD, Andrew Clark, MD 
The Lancet 
Volume 383, Issue 9925, Pages (April 2014)
DOI: /S (13)
Copyright © 2014 Anagnostou et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Anagnostou et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

3. Figure 2 Peanut protein NOAEL by treatment group
Points show the mean and whiskers the 95% CIs. Difference at 6 months p<0·001 (from Mann Whitney U test). NOAEL=no observed adverse effect level.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Anagnostou et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

4. Figure 3
In-vitro basophil activation by peanut before and after desensitisation
Heparinised whole blood was stimulated with a range of peanut protein concentrations (0·001–100 μg/mL) and flow cytometry was used to assess expression as a proportion of CD63 positive cells (A) or by MFI (B) within the basophil population. Differences in areas under the curve were not significant. MFI=mean fluorescent intensity. *After desensitisation.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Anagnostou et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions